Video

Genotypic and Phenotypic Biomarkers in Prostate Cancer

Author(s):

Neal Shore, MD, Carolina Urologic Research Center

A discussion of phenotypic and genotypic biomarkers found in prostate cancer and their implications.

Related Videos
Karine Tawagi, MD,
Louis Crain Garrot, MD
Bradley C. Carthon, MD, PhD
Fred Saad, CQ, MD, FRCS, FCAHS, director, Prostate Cancer Research, Montreal Cancer Institute, Centre Hospitalier de l’Université de Montréal; full professor, Department of Surgery, Université de Montréal; uro-oncologist, Urology Department, University of Montreal Health Center
Bertram Yuh, MD, MISM, MSHCPM
Fred Saad, CQ, MD, FRCS, FCAHS
Fred Saad, CQ, MD, FRCS, FCAHS
Alicia Morgans, MD, MPH
Jacob E. Berchuck, MD
Alicia Morgans, MD, MPH
Related Content
Prostate Cancer
December 11th 2024

CAN-2409 Improves DFS in Intermediate/High-Risk Localized Prostate Cancer

Neeraj Agarwal, MD
July 17th 2023

FDA Approval Insights: Talazoparib Plus Enzalutamide in HRR Gene–Mutated mCRPC

FDA
December 5th 2024

FDA Grants Fast Track Designation to PT217 for Neuroendocrine Prostate Cancer

Andrew J. Armstrong, MD, MSc
June 15th 2023

FDA Approval Insights: Olaparib Plus Abiraterone in BRCA-Mutated mCRPC

Capivasertib Plus Abiraterone/ADT in PTEN-Deficient mHSPC | Image Credit: © Sebastian Kaulitzki - stock.adobe.com
November 25th 2024

Capivasertib Plus Abiraterone/ADT Improves rPFS in PTEN-Deficient mHSPC

FDA
November 21st 2024

FDA Accepts sNDA for Darolutamide Plus ADT in Metastatic Hormone-Sensitive Prostate Cancer